Nova Eye Medical Limited designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally. It offers iTrack, a surgical system for the reduction in intraocular pressure (IOP) in adult patients with open-angle glaucoma; iTrack Advance, a canaloplasty microcatheter; Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma; and 2RT, a proprietary laser technology to treat patients in early/intermediate age-related macular degeneration. The company was formerly known as Ellex Medical Lasers Limited and changed its name to Nova Eye Medical Limited in July 2020. Nova Eye Medical Limited was incorporated in 1970 and is headquartered in Kent Town, Australia.
Stock data | 2023 | Change |
---|---|---|
Price | $0.15270698583557868 | N/A |
Market Cap | $23.82M | N/A |
Shares Outstanding | 155.96M | 7.83% |
Employees | 0 | N/A |
Shareholder Equity | 23.19M | -23.71% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -1.56 | N/A |
P/S Ratio | 2.06 | N/A |
P/B Ratio | 1.03 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -0.4476 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $11.55M | N/A |
Earnings | -$10.38M | N/A |
EPS | -0.0981 | N/A |
Earnings Yield | -0.6424 | N/A |
Gross Margin | 0.8455 | N/A |
Operating Margin | -0.7045 | N/A |
Net income margin | -0.8983 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $20.60M | N/A |
Total Debt | $1.04M | N/A |
Cash on Hand | $5.04M | N/A |
Debt to Equity | 0.2097 | 50.81% |
Cash to Debt | $4.85 | 17.69% |
Current Ratio | $2.33 | -42.33% |